All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma Hub is an independent medical education platform, sponsored by Roche, Sobi, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Lilly and Pfizer. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View lymphoma & CLL content recommended for you
EC approves nivolumab + AVD for cHL
On June 1, 2026, the European Commission (EC) approved nivolumab in combination with doxorubicin + vinblastine + dacarbazine (AVD) for the treatment of adult and adolescent patients aged ≥12 years with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL).1
This approval was based on results from the phase III SWOG 1826 (NCT03907488) trial, assessing the efficacy and safety of nivolumab + AVD compared with brentuximab vedotin (BV) + AVD.1 At a median follow-up of 12.1 months, nivolumab + AVD significantly improved progression-free survival (PFS) vs BV + AVD (hazard ratio [HR], 0.48; 99% confidence interval [CI], 0.27–0.87; p = 0.001).1,2 At a median follow-up of 2.1 years, the 2-year PFS rate was 92% with nivolumab + AVD vs 83% with BV + AVD (HR, 0.45; 95% CI, 0.30–0.65).1,2
Nivolumab was previously approved by the EC in combination with BV for the treatment of patients aged 5–30 years with relapsed/refractory (R/R) cHL after one prior line of therapy.1
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
In patients with R/R LBCL who progress after CAR‑T, which of the following data would most strengthen your confidence in considering BV+R2?
